Experience
We have one of the premier Abbreviated New Drug Application (ANDA)/generic drug patent litigation practices in the country. We have a proven record of success in these cases, having invalidated Pfizer’s patent directed to its multibillion-dollar drug Norvasc®. We also knocked out Daiichi Sankyo Co. Ltd.’s patent on Floxin® otic in a case that resulted in a $5 million award to our generic client. Our attorneys have handled or are presently handling several major ANDA litigations, including cases involving Plavix®, Abilify®, Uroxatral®, Boniva®, Eloxatin®, Ultracet®, Wellbutrin XL®, Strattera®, Adderall XR®, Clarinex®, Amrix®, Enablex® and Cymbalta®. We also have experience in related Food and Drug Administration (FDA) and regulatory matters involving marketing approval for generic drugs under the Hatch-Waxman Act. This experience and understanding of the Hatch-Waxman regulatory scheme is critical in crafting patent litigation strategy.
Our approach to intellectual property litigation, including suits involving patents, is unique in that we provide our clients with a knowledgeable team that handles each case in the most expeditious and cost-effective manner possible. Each case is carefully analyzed to determine the breadth of technical expertise that is necessary. Then, a team led by an experienced trial lawyer is selected and each member of that team brings value and efficiency to the execution of that strategy.
We have more than 90 attorneys dedicated to intellectual property and technology law, including patents, trademarks, copyrights, unfair competition, trade secrets, advertising, licensing, e-commerce, entertainment and media, and intellectual property litigation. We have represented multinational and middle-market corporations in patent, trademark and other intellectual property matters across the country.